Zobrazeno 1 - 7
of 7
pro vyhledávání: '"Chi Leung Chiang"'
Autor:
Tan To Cheung, Chi-Leung Chiang, Kin Pan Au, Albert C. Y. Chan, Kenneth S. H. Chok, Chung Mau Lo
Publikováno v:
World J Clin Cases
BACKGROUND: Graft hepatocellular carcinoma (HCC) recurrence after liver transplant is more frequently encountered. Graft hepatectomy is technically challenging and is associated with high morbidity. Stereotactic body radiation therapy (SBRT) has been
Autor:
Daniel Sánchez, Shing Fung Lee, Chi Leung Chiang, Irene Oi Ling Wong, Bizu Gelaye, Miguel Angel Luque Fernandez, Denise Shuk Ting Cheung, María José Sánchez
Publikováno v:
Digibug. Repositorio Institucional de la Universidad de Granada
instname
BMJ Open
BMJ Open, Vol 11, Iss 10 (2021)
instname
BMJ Open
BMJ Open, Vol 11, Iss 10 (2021)
MALF was supported by the Spanish National Health Institute Carlos III (Instituto de Salud Carlos III -ISCIII), Miguel Servet--I Investigator Grant/Award Number CP17/00206--EU--FEDER.
Objective We evaluated the temporal trend in gender ratios of
Objective We evaluated the temporal trend in gender ratios of
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::7c364648d7df21ad0870e71eff5cd18e
https://researchonline.lshtm.ac.uk/id/eprint/4663372/7/Lee_etal_2021_Trends-in-gender-of-authors.pdf
https://researchonline.lshtm.ac.uk/id/eprint/4663372/7/Lee_etal_2021_Trends-in-gender-of-authors.pdf
Autor:
S Y Yeung, Ka-On Lam, K S Lau, H C Choi, S F Lee, K K Yuen, Siok-Yee Chan, Chi-Leung Chiang, B Y Chan, TS Choy
Publikováno v:
Asia-Pacific Journal of Clinical Oncology. 15:5-13
AIM To investigate treatment patterns and outcomes of metastatic colorectal cancer (mCRC) patients beyond second progression (PD2) since regorafenib and TAS-102 became available in Hong Kong. METHODS The clinical records of consecutive mCRC patients
Autor:
Ren Ji, Kelvin K. Ng, Wenqi Chen, Weihong Yang, Hongtao Zhu, Tan-To Cheung, Chi-Leung Chiang, Tiffany C.L. Wong, Feng-Ming Kong, G. Wu, Chung-Mau Lo
Publikováno v:
Medicine
Stereotactic body radiotherapy (SBRT) is a novel noninvasive treatment for unresectable hepatocellular carcinoma (HCC). Whether its efficacy is comparable to radiofrequency ablation (RFA), a recommended therapy for unresectable HCC, is unknown. The p
Publikováno v:
Chinese clinical oncology. 10(1)
Primary liver cancer includes hepatocellular carcinoma (HCC, 75-85%) and intrahepatic cholangiocarcinoma (10-15%). The vast majority of patients with primary HCC are not candidates for surgical treatment. Surgical resection, liver transplantation and
Publikováno v:
JAMA Network Open
Key Points Question Is pembrolizumab a cost-effective second-line therapy for advanced hepatocellular carcinoma from the US perspective? Findings In this economic evaluation of data from the KEYNOTE-240 randomized trial, the incremental number of qua
Autor:
Francis A. S. Lee, Chi-Leung Chiang, Chi Ming Poon, Stewart Y. Tung, Frank Chi Sing Wong, Yiu Wah Wong, Shing Fung Lee
Publikováno v:
Journal of the Formosan Medical Association, Vol 117, Iss 9, Pp 825-832 (2018)
Background: For advanced rectal cancer with involved or threatened mesorectal fascia (MRF), current standard is pre-operative long course chemoradiotherapy (PLCRT) with either capecitabine or 5-fluorouracil (5-FU). However, few Chinese data on its cl